The legacy of Viagra and its creator , copyright, presents a tangled picture for potential investors. While the revolutionary drug initially fueled enormous profits , its patent has ended, leading to rival alternatives flooding the landscape . This erosion in cost presents a significant hurdle for copyright and any fund considering a large position